Clinical trials: Stage IV
Acute Upper Respiratory Infection
Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection
Phase IV trial,Single-arm, multi-centre clinical trial to assess the efficacy and safety of Fuganlin Oral Liquid in children with acute upper respiratory infection
- Trial name
- NCT02654158
- Testing
- Low-dose of Fuganlin Oral Liquid, High-dose of Fuganlin Oral Liquid
- Where
- China
- Volunteers
- 2,400 people
- Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
Osteoarthritis of the Knee, Total Knee Replacement
Prophecy Guide Outcomes in Total Knee Replacement Surgery
This project aims to assess two different techniques used to position the knee replacement implant during surgery. The patients will be randomised to receive either the following: 1.
- Trial name
- NCT01163708
- Testing
- Prophecy Technique, Navigation System
- Where
- 2 sites in Australia
- Volunteers
- 188 people
- Sponsor
- Global Orthopaedic Technology
Carcinoma, Non-Small-Cell Lung
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
- Trial name
- NCT00059722
- Testing
- ZD6474, ZD1839
- Where
- 48 sites in United States, Argentina and 4 more
- Volunteers
- 160 people
- Sponsor
- Genzyme, a Sanofi Company
Psoriasis
A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
This is a Phase IV open-label study to evaluate the efficacy and safety of SC efalizumab in adult subjects (18 years of age and older) with chronic moderate or worse plaque psoriasis who have had an inadequate response to…
- Trial name
- NCT00336973
- Testing
- efalizumab
- Volunteers
- 73 people
- Sponsor
- Genentech, Inc.
Tumors, Glioma
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in…
- Conditions
- Tumors, Glioma, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00338026
- Testing
- ECO-4601
- Where
- 2 sites in Canada
- Volunteers
- 26 people
- Sponsor
- Thallion Pharmaceuticals
Pancreas Cancer, Pancreatic Cancer
Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Pancreatic Cancer Stage IV, Pancreatic Cancer Stage III
- Trial name
- NCT04137822
- Testing
- IMM-101
- Where
- 2 sites in France, United Kingdom
- Sponsor
- Impatients N.V. trading as myTomorrows
Aspergillus Infections, Candida Infections
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
- Conditions
- Aspergillus Infections, Candida Infections, Fungal Infections
- Trial name
- NCT02631954
- Testing
- Vorico Injection 200mg(Voriconazole), Vfend®(Voriconazole) IV 200mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
HIV Infection
Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity
Study to evaluate the utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity (ABC HSR) in 1800 previously ABC-naive adults with HIV-1 from Europe, Australia and other countries as applicable.
- Trial name
- NCT00340080
- Testing
- Abacavir
- Where
- 254 sites in Australia, Austria and 17 more
- Volunteers
- 1,806 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some patients may develop a resistance to chemotherapy drugs.
- Trial name
- NCT00003253
- Testing
- paclitaxel, antitumor drug screening assay
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Oncotech
Breast Cancer, Lung Cancer
Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90-DOTA-tyr3-octreotide can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00006370
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Unresectable (Stage III) Melanoma
RTA 408 Capsules in Patients With Melanoma - REVEAL
Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths.
- Conditions
- Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
- Trial name
- NCT02259231
- Testing
- Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg)
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Biogen
Ovarian Neoplasms
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
In this study, patients will be randomized to one of three dose regimen groups. Each dose of OvaRex MAb-B43.13 is 2 mg by slow intravenous administration. Group 1 will receive two doses, one month apart.
- Trial name
- NCT00034372
- Testing
- oregovomab
- Where
- 17 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Unither Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer
The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in comparison with chemotherapy alone in patients with advanced non small cell lung cancer.
- Trial name
- NCT00415818
- Testing
- MVA-MUC1-IL2, 1st line Chemotherapy
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 148 people
- Sponsor
- Transgene
Breast Cancer
Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters
RATIONALE: Collecting blood samples and health information from patients with invasive breast cancer and from their brothers and sisters over time may help the study of cancer in the future.
- Trial name
- NCT00445562
- Testing
- biologic sample preservation procedure, informational intervention
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GenBasix Incorporated
Anemia
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
This study will assess the efficacy and safety of methoxy polyethylene glycol-epoetin beta (Mircera) in the maintenance of hemoglobin levels in patients who have previously received treatment with epoetin alfa or darbepoetin…
- Trial name
- NCT00454246
- Testing
- methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
- Where
- 78 sites in United States
- Volunteers
- 111 people
- Sponsor
- Hoffmann-La Roche
Osteogenesis Imperfecta (OI)
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
- Trial name
- EIR (NCT07557446)
- Testing
- AGA2115
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Angitia Biopharmaceuticals Guangzhou Limited
Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV
Phase II Avastin Trial for Stage IIIB/IV NSCLC
This is a randomized, open-label, multicenter study in 160 patients in first line treatment and 114 in second line treatment with advanced or metastatic NSCLC (Stage IIIB/IV).
- Trial name
- NCT00766246
- Testing
- bevacizumab, docetaxel, carboplatin
- Volunteers
- 125 people
- Sponsor
- Pharmatech
Thrombosis, Deep Vein, Pulmonary Embolism
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
Number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with apixaban, according to therapeutic indications approved in Mexico.
- Trial name
- NCT03812835
- Sponsor
- Pfizer
Lung Cancer, Non-Small Cell
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer
This is a phase II, open-label, multicenter, randomized study to evaluate the efficacy and safety of GSK1120212 compared with docetaxel in the second line setting for subjects with locally advanced or metastatic (Stage IV)…
- Trial name
- NCT01362296
- Testing
- GSK1120212, docetaxel
- Where
- 60 sites in United States, France and 6 more
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Atrial Fibrillation
Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)
Primary Objective: To determine whether daily administration of dronedarone started 5-7 days before cardioversion is superior to dronedarone started only after cardioversion with respect to the absence of symptomatic, ECG…
- Trial name
- NCT01026090
- Testing
- Dronedarone
- Where
- 43 sites in Canada
- Volunteers
- 292 people
- Sponsor
- Sanofi